Further identification of disease-relevant targets that are able to protect against neurodegeneration caused by TDP-43 dysfunction offers hope for development of additional improved therapeutics, potentially including antisense approaches, for ALS and FTD [73]. Here, TARDBP is linked to frontotemporal dementia.